We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
SOTIO Biotech announced today that the first patient was dosed in its Phase 2 AURELIO-05 combination trial of nanrilkefusp alfa (previously known as SOT101), an IL-15 superagonist, and cetuximab in patients with colorectal cancer.
AzarGen Biotechnologies (Pty) Ltd (Stellenbosch, South Africa), a company focused on developing human therapeutic proteins using advanced genetic engineering and synthetic biology techniques in plants, is pleased to announce that Dr. Samuel Fourie, an onc
AzarGen Biotechnologies (Pty) Ltd (Stellenbosch, South Africa), a company focused on developing human therapeutic proteins using advanced genetic engineering and synthetic biology techniques in plants, is pleased to announce that Dr. Samuel Fourie, an onc